PRESS RELEASE: axunio Pharma GmbH (Germany) announced today the acquisition of Leith Pharma Group Limited and its subsidiary Leith Healthcare Limited, a UK-based pharmaceutical company.
27 May 2025
axunio announces the acquisition of Leith Healthcare in the United Kingdom
Hamburg, Germany--axunio Pharma GmbH (axunio), a subsidiary of the Tiefenbacher Group, announced today the acquisition of UK-based Leith Pharma Group Limited and its subsidiary Leith Healthcare Limited (Leith).
Leith and axunio have partnered on the UK launch of Lunivia® (eszopiclone) over the last two years, and Leith has two in-licensed brands due to launch over the next year.
Commenting on the acquisition, Ina Kühnemund, Managing Director, axunio said, “this acquisition represents the next step in axunio’s internationalisation strategy, as we establish our own presence in the UK. We see enormous potential in this market and partnering with Leith - whose deep expertise in commercialisation, marketing, and sales is truly exceptional - will be a game-changer for our UK growth story. Together, we are ideally positioned to drive meaningful impact and address patients’ unmet medical needs.”
Founder and Managing Director and of Leith, Richard Baderin commented, “Leith was founded with the goal to bring innovative branded medicines to the UK that could enhance the quality of life for patients. We’ve been fortunate to have axunio as an early partner in our journey and this acquisition is built on a strong alignment in the goals of our companies to champion brands that address unmet needs.”
About Leith
Leith Healthcare Limited is a pharmaceutical company founded in 2023, specialising in in-licensing and commercial partnerships to launch innovative healthcare brands that enhance quality of life for patients in the UK.
About axunio
axunio Pharma GmbH is a subsidiary of the Tiefenbacher Group. axunio’s first product was launched in 2016 and the company now has sales in the home market of Germany and in the Netherlands, Scandinavia, France, Italy, Greece, Ireland and the UK. The main company goal is to provide people having unmet needs and diseases with the same access to affordable and high-quality pharmaceuticals that people with very common needs and diseases already have today.
Contacts
For further information or queries, please contact:
Ina Kühnemund, Managing Director, axunio Pharma
+49 (0)40 38 02 32 14
Richard Baderin, Managing Director, Leith Pharma Group
+44 (0)118 205 4888